For lung cancer, allelic frequencies of TP53 mutations in cfDNA have very wide ranges, from 0.12% to 84.8% [29], suggesting they might either have originated early during the carcinogenic process (in patients with greater VAFs) or much later, even in disseminating CTCs (in patients with lower VAFs). This evidence concerns the gene TP53 and lung cancer.